Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Transfer of Autologous TIL in Metastatic Uveal Melanoma
NCT03467516Phase 2Active, not recruiting
- Start
- May 2018
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in Uveal melanoma (UM). Started May 2018; status: active, not recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03467516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467516.